Phase 1 open-label, multicenter study of first-in-class RORγ agonist LYC-55716 (Cintirorgon): Safety, tolerability, and preliminary evidence of antitumor activity

  • Devalingam Mahalingam
  • , Judy S. Wang
  • , Erika P. Hamilton
  • , John Sarantopoulos
  • , John Nemunaitis
  • , Garry Weems
  • , Laura Carter
  • , Xiao Hu
  • , Marshall Schreeder
  • , H. Jeffrey Wilkins

Research output: Contribution to journal › Article › peer-review

55 Scopus citations

Fingerprint

Dive into the research topics of 'Phase 1 open-label, multicenter study of first-in-class RORγ agonist LYC-55716 (Cintirorgon): Safety, tolerability, and preliminary evidence of antitumor activity'. Together they form a unique fingerprint.

Pharmacology, Toxicology and Pharmaceutical Science